Equities

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)39.19
  • Today's Change0.73 / 1.90%
  • Shares traded1.02m
  • 1 Year change-16.78%
  • Beta0.3749
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy10
Outperform7
Hold7
Sell1
Strong Sell0

Share price forecast in USD

The 22 analysts offering 12 month price targets for Ionis Pharmaceuticals Inc have a median target of 62.00, with a high estimate of 77.00 and a low estimate of 37.00. The median estimate represents a 58.20% increase from the last price of 39.19.
High96.5%77.00
Med58.2%62.00
Low-5.6%37.00

Earnings history & estimates in USD

On Nov 06, 2024, Ionis Pharmaceuticals Inc reported 3rd quarter 2024 losses of -0.95 per share. This result exceeded the -1.16 consensus loss of the 17 analysts covering the company and exceeded last year's 3rd quarter results by 7.77%.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate-374.05%
Ionis Pharmaceuticals Inc reported annual 2023 losses of -2.56 per share on Feb 21, 2024.
Average growth rate-263.64%
More ▼

Revenue history & estimates in USD

Ionis Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 134.00m. This bettered the 130.13m consensus of the 18 analysts covering the company. This was 2.29% above the prior year's 3rd quarter results.
Average growth rate+27.77%
Ionis Pharmaceuticals, Inc. had revenues for the full year 2023 of 787.65m. This was 34.18% above the prior year's results.
Average growth rate-4.33%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.